References
1. Knops RE, Olde Nordkamp LRA, Delnoy P-PHM, et al. Subcutaneous or
Transvenous Defibrillator Therapy. N Engl J Med .
2020;383(6):526-536. doi:10.1056/nejmoa1915932
2. Narula OS, Scherlag BJ, Samet P. Pervenous pacing of the specialized
conducting system in man. His bundle and A-V nodal stimulation.Circulation . 1970;41(1):77-87. doi:10.1161/01.CIR.41.1.77
3. Zanon F, Ellenbogen KA, Dandamudi G, Sharma PS, Huang W, Lustgarten
DL, Tung R, Tada H, Koneru JN, Bergemann T, Fagan DH, Hudnall JH,
Vijayaraman P. Permanent His-bundle pacing: A systematic literature
review and meta-analysis. Europace . 2018;20(11):1819-1826.
doi:10.1093/europace/euy058
4. Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on
cardiac pacing and cardiac resynchronization therapy - Developed by the
Task Force on cardiac pacing and cardiac resynchronization therapy of
the European Society of Cardiology (ESC). Eur Heart J .
2021;42(35):3427–3520. doi:10.1093/eurheartj/ehab364
5. Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L,
Shinn T, St. John Sutton M. Biventricular Pacing for Atrioventricular
Block and Systolic Dysfunction. N Engl J Med .
2013;368(17):1585-1593. doi:10.1056/nejmoa1210356
6. Zweerink A, Zubarev S, Bakelants E, Potyagaylo D, Stettler C,
Chmelevsky M, Lozeron ED, Hachulla AL, Vallée JP, Burri H. His-Optimized
Cardiac Resynchronization Therapy With Ventricular Fusion Pacing for
Electrical Resynchronization in Heart Failure. JACC Clin
Electrophysiol . 2021;7(7):881-892. doi:10.1016/j.jacep.2020.11.029
7. Kutyifa V, Rosero SZ, McNitt S, Polonsky B, Brown MW, Zareba W,
Goldenberg I. Need for pacing in patients who qualify for an implantable
cardioverter-defibrillator: Clinical implications for the subcutaneous
ICD. Ann Noninvasive Electrocardiol . 2020;25(4):e12744.
doi:10.1111/anec.12744
8. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the
diagnosis and treatment of acute and chronic heart failure - Developed
by the Task Force for the diagnosis and treatment of acute and chronic
heart failure of the European Society of Cardiology (ESC). Eur
Heart J . 2021;42(36):3599–3726. doi:10.1002/ejhf.2333
9. Huang J, Patton KK, Prutkin JM. Concomitant Use of the Subcutaneous
Implantable Cardioverter Defibrillator and a Permanent Pacemaker.PACE - Pacing Clin Electrophysiol . 2016;39(11):1240-1245.
doi:10.1111/pace.12955
10. Porterfield C, Dimarco JP, Mason PK. Effectiveness of implantation
of a subcutaneous implantable cardioverter-defibrillator in a patient
with complete heart block and a pacemaker. Am J Cardiol .
2015;115(2):276-278. doi:10.1016/j.amjcard.2014.10.036
11. Kajiyama T, Kondo Y, Nakano M, Chiba T, Kobayashi Y. Concomitant use
and interaction of a subcutaneous implantable defibrillator and
epicardial pacemaker. J Arrhythmia . 2022;38(1):155-156.
doi:10.1002/joa3.12666
12. Ishii N, Nakajima K, Kakuta T, Noda T, Fujita T, Kusano K. One
indication for an extravascular cardiac resynchronization therapy
defibrillator: Lessons from a combination therapy case with epicardial
cardiac resynchronization therapy and a subcutaneous implantable
cardioverter defibrillator. Intern Med . 2021;60(12):1877-1880.
doi:10.2169/internalmedicine.6125-20
13. Gauthey A, Calle S, Accinelli S, Depuydt P, Garnir Q, Scavée C,
Marchandise S, Wauters A, Bordachar P, de Pooter J, de Waroux JB le P.
His bundle pacing for newly acquired pacing needs in patients implanted
with a subcutaneous implantable cardioverter defibrillator: A
feasibility study based on the automated screening score and clinical
cases. J Cardiovasc Electrophysiol . 2020;31(7):1793-1800.
doi:10.1111/jce.14566
14. Fernández-Palacios G, García-Morán E, Sandín-Fuentes M,
García-Granja PE, Rubio J, San Román AJ. The utility of a combined
synchronous atrioventricular leadless pacemaker and subcutaneous
implantable cardiac defibrillator system in bilateral upper limb venous
occlusion. Europace . 2021;23(5):814. doi:10.1093/europace/euaa332
15. Breeman KTN, Swackhamer B, Brisben AJ, Quast AFBE, Carter N, Shuros
A, Soltis B, Koop BE, Burke MC, Wilde AAM, Tjong FVY, Knops RE.
Long-term performance of a novel communicating antitachycardia
pacing–enabled leadless pacemaker and subcutaneous implantable
cardioverter-defibrillator system: A comprehensive preclinical study.Hear Rhythm . 2022;19(5). doi:10.1016/j.hrthm.2022.01.024
16. Elliott MK, Sidhu BS, Mehta VS, Gould J, Martic D, Rinaldi CA. The
importance of leadless pacemaker positioning in relation to subcutaneous
implantable cardioverter-defibrillator sensing in completely leadless
cardiac resynchronization and defibrillation systems. Hear Case
Reports . 2021;7(9):628-632. doi:10.1016/j.hrcr.2021.06.006
17. Nabavizadeh P, Rajsheker S, Attari M. Hybrid subcutaneous and
transvenous approach for cardiac resynchronization defibrillator implant
in a patient with congenital heart disease and tricuspid bioprosthetic.Hear Case Reports . 2020;6(1):27-28.
doi:10.1016/j.hrcr.2019.10.008
18. Srinivasan NT, Segal OR. Biventricular pacing and coronary sinus ICD
lead implantation in a patient with a mechanical tricuspid valve
replacement. J Cardiol Cases . 2015;12(6):180-182.
doi:10.1016/j.jccase.2015.08.004
19. Lüker J, Sultan A, Sreeram N, Brockmeier K, Steven D. Implantation
of a subcutaneous implantable cardioverter defibrillator with right
parasternal electrode position in a patient with D-transposition of the
great arteries and concomitant AAI pacemaker: A case report. Eur
Hear J - Case Reports . 2018;2(3). doi:10.1093/ehjcr/yty099
20. van Opstal J, Geskes G, Debie L. A completely subcutaneous
implantable cardioverter defibrillator system functioning simultaneously
with an endocardial implantable cardioverter defibrillator programmed as
pacemaker. Europace . 2011;13(1):141-142.
doi:10.1093/europace/euq187
21. Marzak H, Morel O, Jesel L. Inappropriate shock due to quadruple
counting in a patient with subcutaneous implantable
cardioverter-defibrillator and a dual-chamber pacemaker.Europace . 2020;22(5):796. doi:10.1093/europace/euaa028
22. Kossidas K, Kalman R, Follis WP, Cooper JM. Managing cross talk
between a subcutaneous implantable cardioverter-defibrillator and a
dual-chamber unipolar pacemaker system. Hear Case Reports .
2017;3(12):579-583. doi:10.1016/j.hrcr.2017.08.004
23. Ip JE, Wu MS, Kennel PJ, Thomas G, Liu CF, Cheung JW, Markowitz SM,
Lerman BB. Eligibility of Pacemaker Patients for Subcutaneous
Implantable Cardioverter Defibrillators. J Cardiovasc
Electrophysiol . 2017;28(5):544-548. doi:10.1111/jce.13182
24. Giammaria M, Lucciola MT, Amellone C, Orlando F, Mazzone G,
Chiarenza S, Lovecchio M, Valsecchi S. Eligibility of cardiac
resynchronization therapy patients for subcutaneous implantable
cardioverter defibrillators. J Interv Card Electrophysiol .
2019;54(1):49-54. doi:10.1007/s10840-018-0437-9
25. Jing R, Jin H, Hua W, Yang S, Hu Y, Zhang S. Association between
subcutaneous implantable cardioverter defibrillator preimplantation
screening and the response to cardiac resynchronization therapy.Korean Circ J . 2020;50(12). doi:10.4070/KCJ.2019.0420